B Levy1, S Collin, N Sennoun, N Ducrocq, A Kimmoun, P Asfar, P Perez, F Meziani. 1. Groupe Choc, Contrat Avenir INSERM 2006, Faculté de Médecine, Nancy Université, 9 Avenue de la Forêt de Haye, BP 184, Vandœuvre-lès-Nancy Cedex, 54505, France. b.levy@chu-nancy.fr
Abstract
PURPOSE: To delineate some of the characteristics of septic vascular hypotension, to assess the most commonly cited and reported underlying mechanisms of vascular hyporesponsiveness to vasoconstrictors in sepsis, and to briefly outline current therapeutic strategies and possible future approaches. METHODS: Source data were obtained from a PubMed search of the medical literature with the following MeSH terms: Muscle, smooth, vascular/physiopathology; hypotension/etiology; shock/physiopathology; vasodilation/physiology; shock/therapy; vasoconstrictor agents. RESULTS: Nitric oxide (NO) and peroxynitrite are crucial components implicated in vasoplegia and vascular hyporeactivity. Vascular ATP-sensitive and calcium-activated potassium channels are activated during shock and participate in hypotension. In addition, shock state is characterized by inappropriately low plasma glucocorticoid and vasopressin concentrations, a dysfunction and desensitization of alpha-receptors, and an inactivation of catecholamines by oxidation. Numerous other mechanisms have been individualized in animal models, the great majority of which involve NO: MEK1/2-ERK1/2 pathway, H(2)S, hyperglycemia, and cytoskeleton dysregulation associated with decreased actin expression. CONCLUSIONS: Many therapeutic approaches have proven their efficiency in animal models, especially therapies directed against one particular compound, but have otherwise failed when used in human shock. Nevertheless, high doses of catecholamines, vasopressin and terlipressin, hydrocortisone, activated protein C, and non-specific shock treatment have demonstrated a partial efficiency in reversing sepsis-induced hypotension.
PURPOSE: To delineate some of the characteristics of septic vascular hypotension, to assess the most commonly cited and reported underlying mechanisms of vascular hyporesponsiveness to vasoconstrictors in sepsis, and to briefly outline current therapeutic strategies and possible future approaches. METHODS: Source data were obtained from a PubMed search of the medical literature with the following MeSH terms: Muscle, smooth, vascular/physiopathology; hypotension/etiology; shock/physiopathology; vasodilation/physiology; shock/therapy; vasoconstrictor agents. RESULTS:Nitric oxide (NO) and peroxynitrite are crucial components implicated in vasoplegia and vascular hyporeactivity. Vascular ATP-sensitive and calcium-activated potassium channels are activated during shock and participate in hypotension. In addition, shock state is characterized by inappropriately low plasma glucocorticoid and vasopressin concentrations, a dysfunction and desensitization of alpha-receptors, and an inactivation of catecholamines by oxidation. Numerous other mechanisms have been individualized in animal models, the great majority of which involve NO: MEK1/2-ERK1/2 pathway, H(2)S, hyperglycemia, and cytoskeleton dysregulation associated with decreased actin expression. CONCLUSIONS: Many therapeutic approaches have proven their efficiency in animal models, especially therapies directed against one particular compound, but have otherwise failed when used in humanshock. Nevertheless, high doses of catecholamines, vasopressin and terlipressin, hydrocortisone, activated protein C, and non-specific shock treatment have demonstrated a partial efficiency in reversing sepsis-induced hypotension.
Authors: Tarek Sharshar; Robert Carlier; Anne Blanchard; Antoine Feydy; Françoise Gray; Michel Paillard; Jean-Claude Raphael; Philippe Gajdos; Djillaii Annane Journal: Crit Care Med Date: 2002-03 Impact factor: 7.598
Authors: Marco Henry Santamaria; Federico Aletti; Joyce B Li; Aaron Tan; Monica Chang; Jessica Leon; Geert W Schmid-Schönbein; Erik B Kistler Journal: J Trauma Acute Care Surg Date: 2017-08 Impact factor: 3.313
Authors: Solène Collin; Nacira Sennoun; Anne-Gaëlle Dron; Mathilde de la Bourdonnaye; Chantal Montemont; Pierre Asfar; Patrick Lacolley; Ferhat Meziani; Bruno Levy Journal: Intensive Care Med Date: 2011-03-03 Impact factor: 17.440
Authors: Erin K Stenson; Natalie Z Cvijanovich; Nick Anas; Geoffrey L Allen; Neal J Thomas; Michael T Bigham; Scott L Weiss; Julie C Fitzgerald; Paul A Checchia; Keith Meyer; Michael Quasney; Mark Hall; Rainer Gedeit; Robert J Freishtat; Jeffrey Nowak; Shekhar S Raj; Shira Gertz; Jocelyn R Grunwell; Hector R Wong Journal: Pediatr Crit Care Med Date: 2018-02 Impact factor: 3.624
Authors: Megan M Vucovich; Robert B Cotton; Elaine L Shelton; Jeremy A Goettel; Noah J Ehinger; Stanley D Poole; Naoko Brown; James L Wynn; Bibhash C Paria; James C Slaughter; Reese H Clark; Mario A Rojas; Jeff Reese Journal: Am J Physiol Heart Circ Physiol Date: 2014-07-03 Impact factor: 4.733